Jiayue Li

Jiayue Li

Auto-generated profile, based on publicly available information

Jiayue Li

School of Medicine, University College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YYYuhao Ye
Yuhao Ye
ZHZhiyu Huang
Zhiyu Huang
MZMaoqing Zhang
Maoqing Zhang
JLJiayue Li
Jiayue Li
YZYiqiong Zhang
Yiqiong Zhang
CLChenghua Lou
Chenghua Lou
The phosphoinositide 3-kinase (PI3K) signaling pathway is well-known for its important role in cancer growth, proliferation and migration. The activation of PI3K pathway is always connected with endocrine resistance and poor prognosis in cancers. Alpelisib, a selective inhibitor of PI3K, has been demonstrated to be effective in combination with endocrine therapy in HR+ PIK3CA-mutated advanced breast cancer in preclinical and clinical trials. Recently, the synergistic effects of alpelisib combined with targeted agents have been widely reported in PIK3CA-mutated cancer cells, such as breast, head and neck squamous cell carcinoma (HNSCC), cervical, liver, pancreatic and lung cancer. However, previous reviews mainly focused on the pharmacological activities of alpelisib in breast cancer. The synergistic therapeutic potential of alpelisib in other cancers has not yet been well reviewed. In this review, an extensive study of related literatures (published until December 20, 2022) regarding the anti-cancer functions and synergistic effects of alpelisib was carried out through the databases. Useful information was extracted. We summarized the preclinical and clinical studies of alpelisib in combination with targeted anti-cancer agents in cancer treatment (excluding breast cancer). The combinations of alpelisib and other targeted agents significantly improved the therapeutic efficacy both in preclinical and clinical studies. Unfortunately, synergistic therapies still could not effectively avoid the possible toxicities and adverse events during treatment. Finally, some prospects for the combination studies in cancer treatment were provided in the paper. Taken together, this review provided valuable information for alpelisib in preclinical and clinical applications.

1 October 2013 in Thrombosis Research
Verified
Journal Article
Closed access
XLXiaoqi Li
Xiaoqi Li
LZLanning Zhang
Lanning Zhang
XCXi Chen
Xi Chen
FQFei Qu
Fei Qu
JLJiayue Li
Jiayue Li
TYTong Yin
Tong Yin

8 November 2023 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
DADisi A
Disi A
JLJiayue Li
Jiayue Li
DZDai Zhang
Dai Zhang
BXBingbing Xiao
Bingbing Xiao
HBHui Bi
Hui Bi
Background: To investigate the prevalence of common sexually transmitted infections (STIs) and the association of STI/human papillomavirus co-infection in young and middle-aged women with previous abnormal cervical findings referred for colposcopy. Methods: 719 cervical-swab cytobrush specimens were obtained from women aged ≤ 50 years who were referred for colposcopy at Peking University First Hospital due to previous abnormal cervical findings. HPV 21 typing and a panel of pathogenic STIs were tested for using the 21 HPV GenoArray Diagnostic Kit (HBGA-21PKG; HybriBio, Ltd., Chaozhou, China) and a nucleic acid STI detection kit (HybriBio Ltd. Guangzhou, China), after which colposcopy with multipoint positioning biopsy was performed. Results: The overall prevalence of STIs among HPV positive women with previous abnormal cervical cancer screening results was 63.7% (458/719), with Ureaplasma parvum serovar 3, Ureaplasma parvum serovar 6 and herpes simplex virus type 2 having significantly higher prevalence among high-risk HPV positive patients (19.3%, Χ2 = 5.725, P = 0.018; 21.5%, Χ2 = 4.439, P = 0.035; 5.7%, Χ2 = 4.184, P = 0.048). Among patients positive for the high-risk human papillomavirus, the prevalence of Neisseria gonorrhoeae infection in human papillomavirus 16/18 positive patients was significantly higher than that in other patients (2.5%, Χ2 = 4.675; P = 0.043). Histopathologically, Chlamydia trachomatis infection was more frequently detected in lower than or equal to low-grade squamous intraepithelial lesion infection status (13.0%, Χ2 = 3.368; P = 0.041). Conclusions: The high prevalence of HPV coinfection with other sexually transmitted pathogens, particularly Ureaplasma parvum serovar 3, Ureaplasma parvum serovar 6, and herpes simplex virus type 2, calls for routine STI screening and effective STI prevention and management in patients with abnormal cervical cancer screening results.

17 October 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
DLDanqing Liu
Danqing Liu
XLXingxing Lv
Xingxing Lv
CZChaoyue Zhao
Chaoyue Zhao
JLJiayue Li
Jiayue Li
JHJinmei Huang
Jinmei Huang
SLShaoqin Liu
Shaoqin Liu
The ECL behaviors of NaBiF4 : Yb3+/Er3+ UCNPs synthesized via a fast and environment-friendly method are reported for the first time. UCNPs-based ECL biosensor shows a wide detection range with low detection limit of 138 CFU mL−1 for E. coli O157 : H7.

30 May 2025 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
FYFangyan Yang
Fangyan Yang
KSKangle Shi
Kangle Shi
XLXiaoyu Liu
Xiaoyu Liu
SWShiyao Wang
Shiyao Wang
HMHongyu Meng
Hongyu Meng
QMQing-gang Meng
Qing-gang Meng